FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1898982375> ?p ?o ?g. }

• W1898982375 endingPage "197" @default.
• W1898982375 startingPage "197" @default.
• W1898982375 abstract "A retrospective analysis of the treatment of childhood acute lymphoblastic leukemia (ALL) in second remission (CR2) was undertaken at our institution to compare the outcome and prognostic factors of patients treated with chemotherapy or allogeneic bone marrow transplantation (BMT).Seventy-five children who suffered a medullary relapse and achieved a second remission were treated with either an unmodified allogeneic HLA-matched sibling BMT after hyperfractionated total body irradiation (TBI) and cyclophosphamide (n = 38) or chemotherapy according to institutional chemotherapy protocols (n = 37). To avoid the bias of survival from the attainment of second remission in favor of BMT, the final comparative statistical analysis used the landmark approach and comprised 37 and 29 patients from the BMT and chemotherapy groups, respectivelyThe disease-free survival (DFS) rate was 62% and 26% at 5 years, respectively, for the BMT and the chemotherapy groups (P = .03), with relapse rates of 19% and 67%, respectively, for these two groups (P = .01). There was an overall advantage for the BMT therapeutic approach, as compared with chemotherapy, for patients with ALL in CR2 (1) for patients with a WBC count (at diagnosis) of 20 x 10(9)/L or higher (DFS, 40% v 0%) and those with a WBC count of less than 20 x 10(9)/L (DFS, 73% v35%), (2) for patients whose duration of CR1 was less than 24 months (DFS 48% v 9%) and for patients whose duration of CR1 was 24 months or longer (DFS, 81% v 37%) and (3) for patients who were initially treated with intensive regimens incorporating more than five chemotherapy agents (DFS, 57% v 20%) and for patients treated with five agents or fewer (DFS, 72% v 32%).In our single-institution series, unmodified HLA-matched allogeneic sibling transplants using hyperfractionated TBI and cyclophosphamide for patients with ALL in CR2 have resulted in superior outcome with a significantly improved probability of DFS and a lower relapse rate, as compared with those for patients treated with chemotherapy, regardless of the duration of first remission, the disease characteristics at diagnosis, or the intensity of prior treatment during first remission." @default.
• W1898982375 created "2016-06-24" @default.
• W1898982375 creator A5010096299 @default.
• W1898982375 creator A5027095419 @default.
• W1898982375 creator A5031035765 @default.
• W1898982375 creator A5034653175 @default.
• W1898982375 creator A5052877133 @default.
• W1898982375 creator A5058476408 @default.
• W1898982375 creator A5067712388 @default.
• W1898982375 creator A5076979099 @default.
• W1898982375 creator A5079103223 @default.
• W1898982375 date "1999-01-01" @default.
• W1898982375 modified "2023-10-02" @default.
• W1898982375 title "Allogeneic Bone Marrow Transplantation Versus Chemotherapy for the Treatment of Childhood Acute Lymphoblastic Leukemia in Second Remission: A Single-Institution Study" @default.
• W1898982375 cites W155212143 @default.
• W1898982375 cites W1809157807 @default.
• W1898982375 cites W1914340996 @default.
• W1898982375 cites W1918033056 @default.
• W1898982375 cites W1939497674 @default.
• W1898982375 cites W1947688836 @default.
• W1898982375 cites W1962271706 @default.
• W1898982375 cites W1966547883 @default.
• W1898982375 cites W1972256295 @default.
• W1898982375 cites W1978319003 @default.
• W1898982375 cites W1978844748 @default.
• W1898982375 cites W1983523898 @default.
• W1898982375 cites W1994028882 @default.
• W1898982375 cites W2000594327 @default.
• W1898982375 cites W2003778995 @default.
• W1898982375 cites W2005279153 @default.
• W1898982375 cites W2008197447 @default.
• W1898982375 cites W2022371214 @default.
• W1898982375 cites W2035614318 @default.
• W1898982375 cites W2037723640 @default.
• W1898982375 cites W2042226495 @default.
• W1898982375 cites W2051703407 @default.
• W1898982375 cites W2077693937 @default.
• W1898982375 cites W2129279704 @default.
• W1898982375 cites W2147996630 @default.
• W1898982375 cites W2156595451 @default.
• W1898982375 cites W2161326960 @default.
• W1898982375 cites W2163596966 @default.
• W1898982375 cites W2172671442 @default.
• W1898982375 cites W2200883957 @default.
• W1898982375 cites W2259248272 @default.
• W1898982375 cites W2322358118 @default.
• W1898982375 cites W2335857054 @default.
• W1898982375 cites W2339110381 @default.
• W1898982375 cites W2401498430 @default.
• W1898982375 cites W2415619833 @default.
• W1898982375 cites W2418923041 @default.
• W1898982375 cites W4234202508 @default.
• W1898982375 cites W4234813891 @default.
• W1898982375 cites W4238048948 @default.
• W1898982375 cites W4243504230 @default.
• W1898982375 cites W43502357 @default.
• W1898982375 doi "https://doi.org/10.1200/jco.1999.17.1.197" @default.
• W1898982375 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10458234" @default.
• W1898982375 hasPublicationYear "1999" @default.
• W1898982375 type Work @default.
• W1898982375 sameAs 1898982375 @default.
• W1898982375 citedByCount "67" @default.
• W1898982375 countsByYear W18989823752012 @default.
• W1898982375 countsByYear W18989823752013 @default.
• W1898982375 countsByYear W18989823752014 @default.
• W1898982375 countsByYear W18989823752016 @default.
• W1898982375 countsByYear W18989823752017 @default.
• W1898982375 countsByYear W18989823752020 @default.
• W1898982375 crossrefType "journal-article" @default.
• W1898982375 hasAuthorship W1898982375A5010096299 @default.
• W1898982375 hasAuthorship W1898982375A5027095419 @default.
• W1898982375 hasAuthorship W1898982375A5031035765 @default.
• W1898982375 hasAuthorship W1898982375A5034653175 @default.
• W1898982375 hasAuthorship W1898982375A5052877133 @default.
• W1898982375 hasAuthorship W1898982375A5058476408 @default.
• W1898982375 hasAuthorship W1898982375A5067712388 @default.
• W1898982375 hasAuthorship W1898982375A5076979099 @default.
• W1898982375 hasAuthorship W1898982375A5079103223 @default.
• W1898982375 hasConcept C126322002 @default.
• W1898982375 hasConcept C141071460 @default.
• W1898982375 hasConcept C143998085 @default.
• W1898982375 hasConcept C167135981 @default.
• W1898982375 hasConcept C195121873 @default.
• W1898982375 hasConcept C2776694085 @default.
• W1898982375 hasConcept C2776755627 @default.
• W1898982375 hasConcept C2778461978 @default.
• W1898982375 hasConcept C2778880498 @default.
• W1898982375 hasConcept C2780007613 @default.
• W1898982375 hasConcept C2781107101 @default.
• W1898982375 hasConcept C2909962599 @default.
• W1898982375 hasConcept C71924100 @default.
• W1898982375 hasConceptScore W1898982375C126322002 @default.
• W1898982375 hasConceptScore W1898982375C141071460 @default.
• W1898982375 hasConceptScore W1898982375C143998085 @default.
• W1898982375 hasConceptScore W1898982375C167135981 @default.
• W1898982375 hasConceptScore W1898982375C195121873 @default.
• W1898982375 hasConceptScore W1898982375C2776694085 @default.
• W1898982375 hasConceptScore W1898982375C2776755627 @default.

• next